This company has been acquired
F-star Therapeutics Balance Sheet Health
Financial Health criteria checks 3/6
Key information
17.3%
Debt to equity ratio
US$9.84m
Debt
| Interest coverage ratio | n/a |
| Cash | US$35.57m |
| Equity | US$56.94m |
| Total liabilities | US$26.78m |
| Total assets | US$83.72m |
Recent financial health updates
No updates
Recent updates
F-star Therapeutics: Running Into A National Security Roadblock
Sep 22F-star Therapeutics falls on extended CFIUS review for Sino-Biopharma sale
Sep 15F-star Therapeutics: A Merger Arbitrage Opportunity Expected To Close Soon
Jul 29F-star enters license deal with Takeda for a cancer immune therapy antibody
Jul 20Need To Know: Analysts Are Much More Bullish On F-star Therapeutics, Inc. (NASDAQ:FSTX) Revenues
May 18
US$26.50: That's What Analysts Think F-star Therapeutics, Inc. (NASDAQ:FSTX) Is Worth After Its Latest Results
Mar 17These Analysts Just Made An Incredible Downgrade To Their F-star Therapeutics, Inc. (NASDAQ:FSTX) EPS Forecasts
Mar 16F-star Therapeutics: Best-In-Class Tetravalent Bispecific Antibody Technology In Cancers
Jan 27F-star Therapeutics under pressure on pricing $65M stock offering
May 07Here's What F-star Therapeutics, Inc.'s (NASDAQ:FSTX) Shareholder Ownership Structure Looks Like
Mar 17Merck KGaA discloses 5.4% stake in F-star Therapeutics
Feb 02Dosing underway in early-stage study of F-star's FS120 in cancer
Dec 03Financial Position Analysis
Short Term Liabilities: FSTX's short term assets ($49.6M) exceed its short term liabilities ($14.7M).
Long Term Liabilities: FSTX's short term assets ($49.6M) exceed its long term liabilities ($12.1M).
Debt to Equity History and Analysis
Debt Level: FSTX has more cash than its total debt.
Reducing Debt: Insufficient data to determine if FSTX's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: FSTX has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: FSTX has less than a year of cash runway if free cash flow continues to reduce at historical rates of 38.7% each year